霍勇,刘峰,向定成

• 1:《急性冠状动脉综合征患者院外长期随访管理共识》专家组
• 2:北京大学第一医院
• 3:上海交通大学医学院苏州九龙医院
• 4:中国人民解放军南部战区总医院

摘要(Abstract)：

近年来，随着我国规范化胸痛中心建设的快速发展，急性冠状动脉综合征（ACS）院内死亡率已明显下降，由于ACS有较高的再发缺血风险和不良心血管事件，出院后的长期随访管理仍面临重大的挑战。目前，尚缺乏公认的专门针对ACS患者院外长期随访管理规范性文件，因此制定本共识，旨在充分应用目前已有的ACS患者出院后管理的一些相关指南基础上，为临床医师提供简便易行的指导性文件，做好院外长期随访和管理。

关键词(KeyWords)： 急性冠状动脉综合征;院外;随访管理;共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 霍勇,刘峰,向定成

参考文献(References)：

• [1]马丽媛，王增武，樊静，等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志，2022,30(7):481-496. DOI:10.3969/j.issn.1004-8812.2022.07.001.
• [2] Song J, Murugiah K, Hu S, et al. Incidence, predictors,and prognostic impact of recurrent acute myocardial infarction in China[J]. Heart, 2020,107(4):313-318. DOI:10.1136/heartjnl-2020-317165.
• [3] Fan F, Li Y, Zhang Y, et al. Chest pain center accreditation is associated with improved in-hospital outcomes of acute myocardial infarction patients in China:findings from the CCC-ACS project[J]. J Am Heart Assoc,2019,8(21):e013384. DOI:10.1161/JAHA.119.013384.
• [4]国家卫生健康委办公厅.关于印发急性冠状动脉综合征分级诊疗技术方案的通知[EB/OL].(2021-9-24)[2023-1-18]. http：//www.nhc.gov.cn/yzygj/s3594q/202111/2a92d8e4cea04c4b94beba4a7fd1fe39.shtml.
• [5] Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events[J]. Arch Intern Med,2003,163(19):2345-2353.DOI:10.1001/archinte.163.19.2345.
• [6] Elbarouni B, Goodman SG, Yan RT, et al. Validation of the Global Registry of Acute Coronary Event(GRACE)risk score for in-hospital mortality in patients with acute coronary syndrome in Canada[J]. Am Heart J,2009,158(3):392-399.DOI:10.1016/j.ahj.2009.06.010.
• [7] Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome:prospective multinational observational study(GRACE)[J]. BMJ,2006,333(7578):1091. DOI:10.1136/bmj.38985.646481.55.
• [8] Poldervaart JM, Langedijk M, Backus BE, et al. Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department[J]. Int J Cardiol,2017,227:656-661. DOI:10.1016/j.ijcard.2016.10.080.
• [9] Hageman SHJ, McKay AJ, Ueda P, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease:the updated SMART2algorithm[J]. Eur Heart J,2022,43(18):1715-1727.DOI:10.1093/eurheartj/ehac056.
• [10] Travin MI, Dessouki A, Cameron T, et al. Use of exercise technetium-99m sestamibi SPECT imaging to detect residual ischemia and for risk stratification after acute myocardial infarction[J]. Am J Cardiol, 1995, 75(10):665-669.DOI:10.1016/s0002-9149(99)80650-x.
• [11] Simpson WG. Biomarker variability and cardiovascular disease residual risk[J]. Curr Opin Cardiol,2019,34(4):413-417. DOI:10.1097/HCO.0000000000000627.
• [12] Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J, 2020, 41(3):407-477. DOI:10.1093/eurheartj/ehz425.
• [13]中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等.冠心病双联抗血小板治疗中国专家共识[J].中华心血管病杂志，2021, 49(5):432-454. DOI:10.3760/cma.j.cn112148-20210125-00088.
• [14]国家卫生计生委合理用药专家委员会，中国药师协会.冠心病合理用药指南（第2版）[J].中国医学前沿杂志（电子版），2018,10(6):1-130. DOI:10.12037/YXQY.2018.06-01.
• [15]中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南（2016年修订版）[J].中国循环杂志，2016, 31(10):937-950. DOI:10.3969/j.issn.1000-3614.2016.10.001.
• [16] Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med,2015,372(25):2387-2397. DOI:10.1056/NEJMoa1410489.
• [17] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J].N Engl J Med,2017,376(18):1713-1722. DOI:10.1056/NEJMoa1615664.
• [18] Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107. DOI:10.1056/NEJMoa1801174.
• [19] Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med,2020,382(16):1507-1519. DOI:10.1056/NEJMoa1912387.
• [20] Ohtsubo T, Shibata R, Kai H, et al. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure:a systematic review and meta-analysis[J]. Hypertens Res,2019,42(5):641-649. DOI:10.1038/s41440-018-0167-5.
• [21] Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin receptor–neprilysin inhibition in acute myocardial infarction[J].N Engl J Med,2021,385(20):1845-1855. DOI:10.1056/NEJMoa2104508.
• [22]中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志，2021, 13(4):315-409.DOI:10.3760/cma.j.cn115791-20210221-00095.
• [23] Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].J Am Coll Cardiol,2022,79(2):e21-e129. DOI:10.1016/j.jacc.2021.09.006.
• [24]中国医师协会心血管内科医师分会，中国心衰中心联盟，《慢性心力衰竭”新四联”药物治疗临床决策路径专家共识》工作组.慢性心力衰竭“新四联”药物治疗临床决策路径专家共识[J].中国循环杂志，2022, 37(8):769-781. DOI:10.3969/j.issn.1000-3614.2022.08.003.
• [25] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modifi cation to reduce cardiovascular risk[J]. Eur Heart J,2020, 41(1):111-188. DOI:10.1093/eurheartj/ehz455.
• [26]中国医师协会心血管内科医师分会.急性冠状动脉综合征患者血脂管理临床路径专家共识[J].中国循环杂志，2020, 35(10):941-947. DOI:10.3969/j.issn.1000-3614.2020.10.001
• [27]中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志，2018, 46(9):680-694. DOI:10.3760/cma.j.issn.0253-3758.2018.09.004.
• [28] Shang P, Liu GG, Zheng X, et al. Association between medication adherence and 1-year major cardiovascular adverse events after acute myocardial infarction in China[J]. J Am Heart Assoc,2019,8(9):e011793. DOI:10.1161/JAHA.118.011793.
• [29] Atkins ER, Du X, Wu Y, et al. Use of cardiovascular prevention treatments after acute coronary syndrome in China and associated factors[J]. Int J Cardiol,2017,241:444-449.DOI:10.1016/j.ijcard.2017.03.057.
• [30]中国医师协会心血管内科医师分会，中国医院协会心脏康复管理专业委员会.慢性冠状动脉综合征患者运动康复分级诊疗中国专家共识[J].中国介入心脏病学杂志，2021, 29(7):361-370. DOI:10.3969/j.issn.1004-8812.2021.07.001.
• [31] Garmendia CM, Miranda RMP, Verello E, et al. Use of a smartphone application to increase adherence to medical treatment[J].Medicina(B Aires), 2021, 81(1):11-15.
• [32] Zijp T, Touw DJ, van Boven JFM. User acceptability and technical robustness evaluation of a novel smart pill bottle prototype designed to support medication adherence[J]. Patient Prefer Adherence,2020, 14:625-634. DOI:10.2147/PPA.?S240443.
• [33]ayl?k F，??nar T, Hay?ro?lu M?，et al.Digital h e a l t h interventions in patient management following acute coronary syndrome:a meta-analysis of the literature[J].Anatol J Cardiol,2023,27(1):2-9. DOI:10.14744/AnatolJCardiol.2022.2254.